Cargando…

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study

BACKGROUND: Canakinumab is a fully human anti-interleukin IL-1beta monoclonal antibody, being investigated for the treatment of rheumatoid arthritis (RA). This multicenter, phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study investigated the efficacy and safety...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alten, Rieke, Gomez-Reino, Juan, Durez, Patrick, Beaulieu, Andre, Sebba, Anthony, Krammer, Gerhard, Preiss, Ralph, Arulmani, Udayasankar, Widmer, Albert, Gitton, Xavier, Kellner, Herbert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152943/ https://www.ncbi.nlm.nih.gov/pubmed/21736751 http://dx.doi.org/10.1186/1471-2474-12-153

Ejemplares similares

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study
por: Schlesinger, Naomi, et al.
Publicado: (2011)

Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study
por: Schlesinger, Naomi, et al.
Publicado: (2011)

Long-term safety, immunogenicity and efficacy comparing FKB327 with the adalimumab reference product in patients with active rheumatoid arthritis: data from randomised double-blind and open-label extension studies
por: Genovese, Mark C, et al.
Publicado: (2020)

Preemptive versus postoperative lumiracoxib for analgesia in ambulatory arthroscopic knee surgery
por: Grifka, Joachim, et al.
Publicado: (2008)

A case of Schnitzler’s syndrome without monoclonal gammopathy successfully treated with canakinumab
por: Fujita, Yuya, et al.
Publicado: (2021)

Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis
por: Nash, Peter, et al.
Publicado: (2016)

Expedited Desensitization to Canakinumab
por: Sanan, Neha, et al.
Publicado: (2020)

Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody
por: Chakraborty, Abhijit, et al.
Publicado: (2012)

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset
por: Ravelli, A, et al.
Publicado: (2014)

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data
por: Ravelli, A, et al.
Publicado: (2014)

OR10-006 - Canakinumab in patients with TRAPS
por: Lachmann, HJ, et al.
Publicado: (2013)

Canakinumab and Lung Cancer: Intriguing, but Is It Real?
por: Chabner, Bruce A., et al.
Publicado: (2018)

Treatment of refractory Yao syndrome with canakinumab
por: Brailsford, Caroline J., et al.
Publicado: (2022)

Physical and Emotional Burden of Rheumatoid Arthritis in Saudi Arabia: An Exploratory Cross-Sectional Study
por: Omair, Mohammed A, et al.
Publicado: (2020)

PW01-012 – Canakinumab in patients with FMF
por: Ugurlu, S, et al.
Publicado: (2013)

Canakinumab for the treatment of different refractory autoinflammatory disorders
por: Grein, Ingrid HR, et al.
Publicado: (2014)

Canakinumab therapy in patients with Familial Mediterranean Fever
por: Ugurlu, S, et al.
Publicado: (2015)

Treatment of systemic-onset juvenile arthritis with canakinumab
por: Peitz, Joachim, et al.
Publicado: (2015)

Canakinumab and cardiovascular outcomes: results of the CANTOS trial
por: Shah, Syed Raza, et al.
Publicado: (2018)

Canakinumab in a subgroup of patients with COVID-19
por: Ucciferri, Claudio, et al.
Publicado: (2020)

Canakinumab for refractory RA: a case report
por: Marketos, Nikolaos, et al.
Publicado: (2018)

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial
por: Conaghan, Philip G, et al.
Publicado: (2013)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
por: Combe, Bernard, et al.
Publicado: (2021)

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26–52, including a treatment switch from reference ADL to PF-06410293
por: Fleischmann, Roy M, et al.
Publicado: (2021)

Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment
por: Taylor, Peter C, et al.
Publicado: (2018)

Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes
por: Taylor, Peter C., et al.
Publicado: (2022)

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics
por: Ait-Oudhia, S, et al.
Publicado: (2012)

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2020)

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017
por: Lindner, Lisa, et al.
Publicado: (2020)

P02-008 - Dramatic response to canakinumab in MKD
por: Makay, B, et al.
Publicado: (2013)

OR7-005 – Canakinumab in childhood colchicine resistant FMF
por: Hashkes, PJ, et al.
Publicado: (2013)

PReS-FINAL-2330: Canakinumab treatment in patients with HIDS
por: Antón, J, et al.
Publicado: (2013)

Clinical response to the canakinumab in crohn’s disease related artrhritis
por: Gündüz, Zübeyde, et al.
Publicado: (2014)

Clinical experiences with canakinumab as a treatment for autoinflammatory disorders
por: Saperia, C, et al.
Publicado: (2015)

Efficacy of canakinumab in mild or severe COVID‐19 pneumonia
por: Katia, Falasca, et al.
Publicado: (2021)

Long-term efficacy, safety, and immunogenicity of the adalimumab biosimilar, PF-06410293, in patients with rheumatoid arthritis after switching from reference adalimumab (Humira®) or continuing biosimilar therapy: week 52–92 data from a randomized, double-blind, phase 3 trial
por: Fleischmann, Roy M., et al.
Publicado: (2021)

Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis
por: Alten, Rieke, et al.
Publicado: (2015)

PReS-FINAL-2157: Efficacy of canakinumab in the treatment of systemic juvenile idiopathic arthritis: a 12-week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2013)

Efficacy of canakinumab in biologic-naïve versus previously biologic-exposed SJIA patients: a 12 week pooled post-hoc analysis
por: Quartier, P, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_7i0kge0evhgnu4o9en6u2o5vnc